Literature DB >> 11579114

Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.

S K McDonnell1, D J Schaid, J L Myers, C S Grant, J H Donohue, J E Woods, M H Frost, J L Johnson, D L Sitta, J M Slezak, T B Crotty, R B Jenkins, T A Sellers, L C Hartmann.   

Abstract

PURPOSE: To estimate the efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. PATIENTS AND METHODS: We followed the course of 745 women with a first breast cancer and a family history of breast and/or ovarian cancer who underwent contralateral prophylactic mastectomy at the Mayo Clinic between 1960 and 1993. Family history information and cancer follow-up information were obtained from the medical record, a study-specific questionnaire, and telephone follow-up. Life-tables for contralateral breast cancers, which consider age at first breast cancer, current age, and type of family history, were used to calculate the number of breast cancers expected in our cohort had they not had a prophylactic mastectomy.
RESULTS: Of the 745 women in our cohort, 388 were premenopausal (age < 50 years) and 357 were post- menopausal. Eight women developed a contralateral breast cancer. Six events were observed among the premenopausal women, compared with 106.2 predicted, resulting in a risk reduction of 94.4% (95% confidence interval [CI], 87.7% to 97.9%). For the 357 postmenopausal women, 50.3 contralateral breast cancers were predicted, whereas only two were observed, representing a 96.0% risk reduction (95% CI, 85.6% to 99.5%).
CONCLUSION: The incidence of contralateral breast cancer seems to be reduced significantly after contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.

Entities:  

Mesh:

Year:  2001        PMID: 11579114     DOI: 10.1200/JCO.2001.19.19.3938

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  59 in total

Review 1.  The role of BRCA mutation testing in determining breast cancer therapy.

Authors:  Alison H Trainer; Craig R Lewis; Kathy Tucker; Bettina Meiser; Michael Friedlander; Robyn L Ward
Journal:  Nat Rev Clin Oncol       Date:  2010-11-09       Impact factor: 66.675

2.  Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.

Authors:  Min Yi; Kelly K Hunt; Banu K Arun; Isabelle Bedrosian; Angelica Gutierrez Barrera; Kim-Anh Do; Henry M Kuerer; Gildy V Babiera; Elizabeth A Mittendorf; Kaylene Ready; Jennifer Litton; Funda Meric-Bernstam
Journal:  Cancer Prev Res (Phila)       Date:  2010-07-20

Review 3.  Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis.

Authors:  Oluwadamilola Motunaryo Fayanju; Carolyn R T Stoll; Susan Fowler; Graham A Colditz; Julie A Margenthaler
Journal:  Ann Surg       Date:  2014-12       Impact factor: 12.969

Review 4.  Contralateral prophylactic mastectomy in breast cancer: what to discuss with patients.

Authors:  Giacomo Montagna; Monica Morrow
Journal:  Expert Rev Anticancer Ther       Date:  2020-02-28       Impact factor: 4.512

5.  Contralateral prophylactic mastectomy in young women with breast cancer: a population-based analysis of predictive factors and clinical impact.

Authors:  A Bouchard-Fortier; N N Baxter; R Sutradhar; K Fernandes; X Camacho; P Graham; M L Quan
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

6.  Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy.

Authors:  Min Yi; Funda Meric-Bernstam; Lavinia P Middleton; Banu K Arun; Isabelle Bedrosian; Gildy V Babiera; Rosa F Hwang; Henry M Kuerer; Wei Yang; Kelly K Hunt
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

Review 7.  [Hereditary breast cancer].

Authors:  B Schlehe; R Schmutzler
Journal:  Chirurg       Date:  2008-11       Impact factor: 0.955

8.  Impact of Genetic Counseling and Testing on Altruistic Motivations to Test for BRCA1/2: a Longitudinal Study.

Authors:  Rahul Garg; Joseph Vogelgesang; Kimberly Kelly
Journal:  J Genet Couns       Date:  2015-11-18       Impact factor: 2.537

9.  Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction.

Authors:  Marc D Schwartz; Heiddis B Valdimarsdottir; Tiffani A DeMarco; Beth N Peshkin; William Lawrence; Jessica Rispoli; Karen Brown; Claudine Isaacs; Suzanne O'Neill; Rebecca Shelby; Sherry C Grumet; Margaret M McGovern; Sarah Garnett; Heather Bremer; Suzanne Leaman; Kathryn O'Mara; Sarah Kelleher; Kathryn Komaridis
Journal:  Health Psychol       Date:  2009-01       Impact factor: 4.267

Review 10.  Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda.

Authors:  Bettina Meiser; Kathy Tucker; Michael Friedlander; Kristine Barlow-Stewart; Elizabeth Lobb; Christobel Saunders; Gillian Mitchell
Journal:  Breast Cancer Res       Date:  2008-11-28       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.